DAFTAR PUSTAKA

1. He S, Zhou C, Lu D, Yang H, Xu H, Wu G, et al. Relationship between chest CT

manifestations and immune response in COVID-19 patients. Int J Infect Dis [Internet].
2020;98:125–9. Available from: https://doi.org/10.1016/j.ijid.2020.06.059
2. Chowdhury MA, Hossain N, Kashem MA, Shahid MA, Alam A. Immune response in
COVID-19: A review. J Infect Public Health [Internet]. 2020;13(11):1619–29. Available
from: https://doi.org/10.1016/j.jiph.2020.07.001
3. CNN Indonesia. Positif Covid-19 Bertambah 20.004 Kasus, Kematian 1.348 Orang.
cnnindonesia.com [Internet]. 2021; Available from:
https://www.cnnindonesia.com/nasional/20210820151712-20-683069/positif-covid-19-
bertambah-20004-kasus-kematian-1348-orang
4. Zhang B, Yue D, Wang Y, Wang F, Wu S, Hou H. The dynamics of immune response in
COVID-19 patients with different illness severity. J Med Virol. 2021;93(2):1070–7.
5. Casadevall A, Pirofski LA. In fatal COVID-19, the immune response can control the
virus but kill the patient. Proc Natl Acad Sci U S A. 2020;117(48):30009–11.
6. Catanzaro M, Fagiani F, Racchi M, Corsini E, Govoni S, Lanni C. Immune response in
COVID-19: addressing a pharmacological challenge by targeting pathways triggered by
SARS-CoV-2. Signal Transduct Target Ther [Internet]. 2020;5(1). Available from:
http://dx.doi.org/10.1038/s41392-020-0191-1
7. Tufan A, Avanoğlu Güler A, Matucci-Cerinic M. Covid-19, immune system response,
hyperinflammation and repurposinantirheumatic drugs. Turkish J Med Sci. 2020;50(SI-
1):620–32.
8. Fill Malfertheiner S, Brandstetter S, Roth S, Harner S, Buntrock-Döpke H, Toncheva AA,
et al. Immune response to SARS-CoV-2 in health care workers following a COVID-19
outbreak: A prospective longitudinal study. J Clin Virol. 2020;130(January).
9. Chalmers JD, Chotirmall SH. Rewiring the immune response in COVID-19. Am J Respir
Crit Care Med. 2020;202(6):784–6.
10. Maggi E, Canonica GW, Moretta L. COVID-19: Unanswered questions on immune
response and pathogenesis. J Allergy Clin Immunol [Internet]. 2020;146(1):18–22.
Available from: https://doi.org/10.1016/j.jaci.2020.05.001

21
11. Alnefaie A, Albogami S. Current approaches used in treating COVID-19 from a
molecular mechanisms and immune response perspective. Saudi Pharm J [Internet].
2020;28(11):1333–52. Available from: https://doi.org/10.1016/j.jsps.2020.08.024
12. Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Brüggen MC, et al.
Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in
COVID-19. Allergy Eur J Allergy Clin Immunol. 2020;75(7):1564–81.
13. Wang, L., Wang, Y., Ye, D., Liu, Q., 2020. Review of the 2019 novel coronavirus
(SARS-CoV-2) based on current evidence. Int. J. Antimicrob. Agents 55, 105948.
https://doi.org/10.1016/j.ijantimicag.2020.105948
14. Shereen, M.A., Khan, S., Kazmi, A., Bashir, N., Siddique, R., 2020. COVID-19 infection:
origin, transmission, and characteristics of human coronaviruses. J. Adv. Res.
15. Oguh, C.E., Obiwulu, E.N.O., Oniwon, W.O., Okekeaji, U., Ugwu, C.V., Umezinwa,
O.J., Osuji, C.A., 2020. Structure and Function of COVID-19 Encode Proteins in the
Transcription and Replication Mechanism with Its Preventive Measures and Propose
Efficacy Treatments: A Critical Systematic Review. Asian. J. Immunol.,15–29
16. Rothan, H.A., Byrareddy, S.N., 2020. The epidemiology and pathogenesis of coronavirus
disease (COVID-19) outbreak. J. Autoimmun. 102433.
17. Ahn, D.-G., Shin, H.-J., Kim, M.-H., Lee, S., Kim, H.-S., Myoung, J., Kim, B.-T., Kim,
S.-J., 2020. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for
Novel Coronavirus Disease 2019 (COVID-19). J. Microbiol. Biotechnol. 30, 313–
324.https://doi.org/10.4014/jmb.2003.03011.
18. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al.
Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2
admitted to ICUs of the Lombardy Region, Italy. JAMA.
2020;323:1574-81,http://dx.doi.org/10.1001/jama.2020.5394
19. Lippi G, Mattiuzzi C, Sanchis-Gomar F, Henry BM. Clinical and demographic
characteristics of patients dyingfrom COVID-19 in Italy versus China. J Med
Virol. 2020, http://dx.doi.org/10.1002/jmv.25860
20. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel Coronavirus
from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727-33,
http://dx.doi.org/10.1056/NEJMoa2001017

22
21. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk
factors for mortality of adult in patients with COVID-19 in Wuhan, China: a
retrospective cohort study. Lancet. 2020;395:1054---62,
http://dx.doi.org/10.1016/S0140-6736(20)30566-3
22. Lau H, Khosrawipour T, Kocbach P, Ichii H, Bania J,Khosrawipour V. Evaluating
the massive underreporting and undertesting of COVID-19 cases in multiple global
epicenters. Pulmonol. 2020, http://dx.doi.org/10.1016/j.pulmoe.2020.05.015.
23. 16, 18, 2123,24, 2627
24. Tang NL, Chan PK, Wong CK, et al. Early enhanced expression of
interferoninducible protein 10 (CXCL-10) and other chemokines predicts adverse
outcome in severe acute respiratory syndrome. Clin Chem 2005;51:2333–40.
25. Wu Z, McGoogan JM. Characteristics of and important lessons from the
coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of
72314 cases from the Chinese Center for Disease Control and Prevention. JAMA
2020 [in press].
26. Wang D, Hu B, Hu C, Chang Hu, Zhu F, Liu X, et al. Clinical characteristics of
138 hospitalized patients with 2019 novel coronavirus-infected pneumoniain Wuhan,
China. JAMA 2020
27. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and
clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,
China: a descriptive study. Lancet 2020 (January).
28. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of
patients infected with 2019 novel coronavirus in Wuhan, China. Lancet
2020;395(10223):49.
29. Qin Yin, Zhen Fu, Jiao Xie, Jixing Zhang, et al. April Analysis of risk factors of
severe COVID-19 patients; 2020
30. Liu Y, Du X, Chen J, Jin Y, Peng L, Wang H, et al. Neutrophil-tolymphocyte
ratio as an independent risk factor for mortality in hospitalized patients with
COVID-19. J Infect. 2020;81:e6---12, http://dx.doi.org/10.1016/j.jinf.2020.04.002.

23
31. Henry BM, Cheruiyot I, Vikse J, Mutua V, Kipkorir V, Benoit J, et al.
 Lymphopenia and neutrophilia at admission predicts severity and mortality in
patients with COVID-19: a meta-analysis. Acta Biomed. 2020;91:e2020008,
http://dx.doi.org/10.23750/abm.v91i3.10217
32. Swatantra Kumar, Rajni Nyodu, Maurya Vimal K, Saxena Shailendra K. Host immune
response and immunobiology of human SARS-CoV-2 infection. In: Coronavirus
disease 2019 (COVID-19); 2020. p. 43–53.
33. García LF. Immune Response, Inflammation, and the Clinical Spectrum of COVID-19.
Front. Immunol. 2020. 11:1441.doi: 10.3389/fimmu.2020.01441
34. Cui N, Yan R, Qin C and Zhao J. Clinical Characteristics and Immune Responses of 137
Deceased Patients With COVID-19: A Retrospective Study. Front. Cell. Infect.
Microbiol. 2020. 10:595333. doi: 10.3389/fcimb.2020.595333
35. Han H, Xu Z, Cheng X, Zhong Y, Yuan L, Wang F, et al. Descriptive, retrospective study
of the clinical characteristics of asymptomatic COVID-19 patients. MSphere. 2020.
5:e00922-20.https://doi.org/10.1128/mSphere.00922-20
36. Xie L, Wu Q, Lin Q, Liu X, Lin W, Hao S, et al. Dysfunction of adaptive immunity is
related to severity of COVID-19: a retrospective study. Ther Adv Respir Dis. 2020, Vol.
14: 1–15. https://doi.org/10.1177/1753466620942129
37. Lu W, Wu P, He L, Meng Y, Wu P, Ding W et al. Dynamic Antibody Responses in
Patients with Different Severity of COVID-19: A Retrospective Study. Infect Dis Ther.
2021. 10:1379–1390 https://doi.org/10.1007/s40121-021-00423-9
38. Hou H, Wang T, Zhang B, Luo Y, Mao L, Wang F, et al. Detection of IgM and IgG
antibodies in patients with coronavirus disease 2019. Clinical & Translational
Immunology. 2020;9: e1136. doi: 10.1002/cti2.1136
39. Zhao Y, Qin L, Zhang P, Li K, Liang L, Sun J, et al. Longitudinal COVID-19 profiling
associates IL-1RA and IL-10 with disease severity and RANTES with mild disease. JCI
Insight. 2020;5(13):e139834. https://doi.org/10.1172/jci.insight.139834
40. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological
features of severe and moderate coronavirus disease 2019. J Clin Invest.
2020;130(5):2620–2629. https://doi.org/10.1172/JCI137244

24
41. Song J, Zhang C, Fan X, Meng F, Xu Z, Xia P, et al. Immunological and inflammatory
profiles in mild and severe cases of COVID-19. Nature Communications. 2020. 11:3410.
 https://doi.org/10.1038/s41467-020-17240-2
42. Ghazavi A, Ganji A, Keshavarzian N, Rabiemajd S, Mosayebi G. Cytokine profile and
disease severity in patients with COVID-19. Cytokine 137. 2021. 155323.
https://doi.org/10.1016/j.cyto.2020.155323
43. Wang F, Hou H, Luo Y, Tang G, Wu S, Huang M, et al. The laboratory tests and host
immunity of COVID-19 patients with different severity of illness 2020;5(10):e137799.
https://doi.org/10.1172/jci.insight.137799
44. Song C, Xu J, He J ad Lu Y. Immune dysfunction following COVID-19, especially in
severe patients. Scientific Reports. 2020. 10:15838. https://doi.org/10.1038/s41598-020-
72718-9
45. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune
responses. J Med Virol. (2020) 92:424–32. doi: 10.1002/jmv.25685
46. Behrens EM, Koretzky GA. Review: cytokine storm syndrome: looking toward the
precision medicine Era. Arthritis Rheumatol. 2017;69(6):1135-43